Cream shows promise for rare skin condition, but study halted early
Disease control
Terminated
This study tested a sirolimus cream applied daily for 12 weeks to treat facial angiofibromas (benign skin growths) in children with tuberous sclerosis complex. The trial aimed to see if the cream could safely reduce redness and lesion size. However, the study was terminated early…
Phase: PHASE2 • Sponsor: Aucta Pharmaceuticals, Inc • Aim: Disease control
Last updated May 17, 2026 08:14 UTC